Sugammadex + Neostigmine + Glycopyrrolate + Rocuronium
ApprovedRecruiting 0 views this week 0 watching⚡ Active
Interest: 50/100
50
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Spine Surgery
Conditions
Spine Surgery, Reversal of Neuromuscular Blockade, Urinary Retention Postoperative
Trial Timeline
Aug 3, 2023 → Jun 1, 2026
NCT ID
NCT05887375About Sugammadex + Neostigmine + Glycopyrrolate + Rocuronium
Sugammadex + Neostigmine + Glycopyrrolate + Rocuronium is a approved stage product being developed by Merck for Spine Surgery. The current trial status is recruiting. This product is registered under clinical trial identifier NCT05887375. Target conditions include Spine Surgery, Reversal of Neuromuscular Blockade, Urinary Retention Postoperative.
What happened to similar drugs?
1 of 1 similar drugs in Spine Surgery were approved
Approved (1) Terminated (0) Active (0)
Hype Score Breakdown
Clinical
20
Activity
15
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05887375 | Approved | Recruiting |
Competing Products
2 competing products in Spine Surgery
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| sugammadex + Neostigmine | Merck | Approved | 43 |
| Dexmedetomidine + Normal Saline | Pfizer | Pre-clinical | 26 |